Literature DB >> 15588251

K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom.

Stéphanie Mouhat1, Violeta Visan, S Ananthakrishnan, Heike Wulff, Nicolas Andreotti, Stephan Grissmer, Hervé Darbon, Michel De Waard, Jean-Marc Sabatier.   

Abstract

OSK1 (alpha-KTx3.7) is a 38-residue toxin cross-linked by three disulphide bridges that was initially isolated from the venom of the Asian scorpion Orthochirus scrobiculosus. OSK1 and several structural analogues were produced by solid-phase chemical synthesis, and were tested for lethality in mice and for their efficacy in blocking a series of 14 voltage-gated and Ca2+-activated K+ channels in vitro. In the present paper, we report that OSK1 is lethal in mice by intracerebroventricular injection, with a LD50 (50% lethal dose) value of 2 microg/kg. OSK1 blocks K(v)1.1, K(v)1.2, K(v)1.3 channels potently and K(Ca)3.1 channel moderately, with IC50 values of 0.6, 5.4, 0.014 and 225 nM respectively. Structural analogues of OSK1, in which we mutated positions 16 (Glu16-->Lys) and/or 20 (Lys20-->Asp) to amino acid residues that are conserved in all other members of the alpha-KTx3 toxin family except OSK1, were also produced and tested. Among the OSK1 analogues, [K16,D20]-OSK1 (OSK1 with Glu16-->Lys and Lys20-->Asp mutations) shows an increased potency on K(v)1.3 channel, with an IC50 value of 0.003 nM, without loss of activity on K(Ca)3.1 channel. These data suggest that OSK1 or [K16,D20]-OSK1 could serve as leads for the design and production of new immunosuppressive drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15588251      PMCID: PMC1134677          DOI: 10.1042/BJ20041379

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  35 in total

Review 1.  Diversity of folds in animal toxins acting on ion channels.

Authors:  Stéphanie Mouhat; Besma Jouirou; Amor Mosbah; Michel De Waard; Jean-Marc Sabatier
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

2.  Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo.

Authors:  G C Koo; J T Blake; A Talento; M Nguyen; S Lin; A Sirotina; K Shah; K Mulvany; D Hora; P Cunningham; D L Wunderler; O B McManus; R Slaughter; R Bugianesi; J Felix; M Garcia; J Williamson; G Kaczorowski; N H Sigal; M S Springer; W Feeney
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

3.  Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3.

Authors:  H Rauer; S Grissmer
Journal:  Mol Pharmacol       Date:  1996-12       Impact factor: 4.436

4.  Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins.

Authors:  J Aiyar; J M Withka; J P Rizzi; D H Singleton; G C Andrews; W Lin; J Boyd; D C Hanson; M Simon; B Dethlefs
Journal:  Neuron       Date:  1995-11       Impact factor: 17.173

5.  Synthesis and characterization of kaliotoxin. Is the 26-32 sequence essential for potassium channel recognition?

Authors:  R Romi; M Crest; M Gola; F Sampieri; G Jacquet; H Zerrouk; P Mansuelle; O Sorokine; A Van Dorsselaer; H Rochat
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

6.  Three-dimensional structure of toxin OSK1 from Orthochirus scrobiculosus scorpion venom.

Authors:  V A Jaravine; D E Nolde; M J Reibarkh; Y V Korolkova; S A Kozlov; K A Pluzhnikov; E V Grishin; A S Arseniev
Journal:  Biochemistry       Date:  1997-02-11       Impact factor: 3.162

7.  Cobatoxin 1 from Centruroides noxius scorpion venom: chemical synthesis, three-dimensional structure in solution, pharmacology and docking on K+ channels.

Authors:  Besma Jouirou; Amor Mosbah; Violeta Visan; Stephan Grissmer; Sarrah M'Barek; Ziad Fajloun; Jurphaas Van Rietschoten; Christiane Devaux; Hervé Rochat; Guy Lippens; Mohamed El Ayeb; Michel De Waard; Kamel Mabrouk; Jean-Marc Sabatier
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

8.  The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.

Authors:  Stéphanie Mouhat; Amor Mosbah; Violeta Visan; Heike Wulff; Muriel Delepierre; Hervé Darbon; Stephan Grissmer; Michel De Waard; Jean-Marc Sabatier
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

9.  P05, a new leiurotoxin I-like scorpion toxin: synthesis and structure-activity relationships of the alpha-amidated analog, a ligand of Ca(2+)-activated K+ channels with increased affinity.

Authors:  J M Sabatier; H Zerrouk; H Darbon; K Mabrouk; A Benslimane; H Rochat; M F Martin-Eauclaire; J Van Rietschoten
Journal:  Biochemistry       Date:  1993-03-23       Impact factor: 3.162

10.  Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.

Authors:  S Grissmer; A N Nguyen; J Aiyar; D C Hanson; R J Mather; G A Gutman; M J Karmilowicz; D D Auperin; K G Chandy
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

View more
  38 in total

1.  Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.

Authors:  Zoltan Varga; Georgina Gurrola-Briones; Ferenc Papp; Ricardo C Rodríguez de la Vega; Gustavo Pedraza-Alva; Rajeev B Tajhya; Rezso Gaspar; Luis Cardenas; Yvonne Rosenstein; Christine Beeton; Lourival D Possani; Gyorgy Panyi
Journal:  Mol Pharmacol       Date:  2012-05-23       Impact factor: 4.436

2.  Scorpion toxins prefer salt solutions.

Authors:  Azadeh Nikouee; Morteza Khabiri; Lukasz Cwiklik
Journal:  J Mol Model       Date:  2015-10-16       Impact factor: 1.810

3.  Scorpion Potassium Channel-blocking Defensin Highlights a Functional Link with Neurotoxin.

Authors:  Lanxia Meng; Zili Xie; Qian Zhang; Yang Li; Fan Yang; Zongyun Chen; Wenxin Li; Zhijian Cao; Yingliang Wu
Journal:  J Biol Chem       Date:  2016-01-27       Impact factor: 5.157

Review 4.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 5.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

6.  Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.

Authors:  Wilson Edwards; Wai-Ping Fung-Leung; Chichi Huang; Ellen Chi; Nancy Wu; Yi Liu; Michael P Maher; Rachelle Bonesteel; Judith Connor; Ross Fellows; Elena Garcia; Jerry Lee; Lu Lu; Karen Ngo; Brian Scott; Hong Zhou; Ronald V Swanson; Alan D Wickenden
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

7.  Complexes of Peptide Blockers with Kv1.6 Pore Domain: Molecular Modeling and Studies with KcsA-Kv1.6 Channel.

Authors:  O V Nekrasova; A D Volyntseva; K S Kudryashova; V N Novoseletsky; E A Lyapina; A V Illarionova; S A Yakimov; Yu V Korolkova; K V Shaitan; M P Kirpichnikov; A V Feofanov
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-17       Impact factor: 4.147

8.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

Review 9.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 10.  Molecular and cellular basis of small--and intermediate-conductance, calcium-activated potassium channel function in the brain.

Authors:  P Pedarzani; M Stocker
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.